Skip to content
19 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · story · 19 November

AstraZeneca pledges $200m to Tempus AI as their agreement is extended

AstraZeneca · 10 headlines from 7 outlets, on 19 November 2026.

The story

+4.5positive
Headlines10
Outlets7
Days119 November

Outlets report a five-year extension through 2031.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 7 outlets

Every outlet, by impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

Every outlet, by impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
TradingView4.3
MarketScreener5.0
MLQ.ai5.0
tokenpost.com5.0
Investing.com UK4.2
TipRanks4.2
Moomoo3.3
OutletHeadlinesAverage tone
TradingView3+4.3
MarketScreener2+5.0
MLQ.ai1+5.0
tokenpost.com1+5.0
Investing.com UK1+4.2
TipRanks1+4.2
Moomoo1+3.3

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 1 day, strongest headlines first

Thursday 19 November 202610 headlines · Outlets report a five-year extension through 2031.+4.5
ToneWhat the article reported, and why it scored that waySource
+5.0Services contract prolonged for several years.MarketScreener (opens the article) ↗
+5.0Oncology agreement extended, showing continued investment.TradingView (opens the article) ↗
+5.0Sizeable multi-year data commitment supports oncology pipeline work.MLQ.ai (opens the article) ↗
+5.0Data partnership with AI firm continues, supporting oncology research.MarketScreener (opens the article) ↗
+5.0Oncology data deal renewed with large commitment.tokenpost.com (opens the article) ↗
+4.7Partnership prolonged with five-year funding commitment.TradingView (opens the article) ↗
+4.2Amended deal includes new multi-year spending commitment.Investing.com UK (opens the article) ↗
+4.2Services agreement extended.TipRanks (opens the article) ↗
2 more headlines that day
ToneWhat the article reported, and why it scored that waySource
+3.3Formal amendment to existing services contract.TradingView (opens the article) ↗
+3.3Contract amendment continues existing relationship.Moomoo (opens the article) ↗

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 19 November · 909 headlines · 82 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt